NEUR-EX
DEAD

Serial Number

97173248

Owner

Aruna Bio, Inc.

Attorney

Devon E. White

Filing Date

Dec 15, 2021

Add to watchlist:

No watchlists yet
View on USPTO

NEUR-EX Trademark

Serial Number: 97173248

NEUR-EX is a trademark filed by Aruna Bio, Inc. on December 15, 2021. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Aruna Bio, Inc.

184 Collins Industrial Blvd, Suite A
Athens, GA 30601

Entity Type: 03

Trademark Details

Filing Date

December 15, 2021

Registration Date

Not Registered

Goods & Services

Research and development in the field of neural exosome-based therapeutics for the treatment of neurodegenerative diseases; Research and development in the field of neural exosome-based platforms to harness the inherent properties of neural exosomes for their therapeutic and delivery capabilities; Research and development in the field of neural exosomes to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosomes, namely, to engineer exosomes to carry various biologically active drug molecules, target specific cell types or cellular pathways, and enhance the value of existing drug modalities; Research and development in the field of neural exosome platforms to reduce pro-inflammatory t-cells, increase anti-inflammatory t-cells, increase anti-inflammatory macrophages, decrease pro-inflammatory microglia, decrease acute and chronic inflammation, protect axons and neurons, and restore neuronal and myelin integrity for the treatment of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosome platforms to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of next-generation neural exosomes to enhance blood-brain barrier penetration and/or enhance the properties of cell-targeting exosomes

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Nov 21, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Nov 21, 2024 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 7, 2024 GNFN
FINAL REFUSAL E-MAILED
Aug 7, 2024 GNFR
FINAL REFUSAL WRITTEN
Aug 7, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 8, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 8, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 11, 2023 GNRN
NON-FINAL ACTION E-MAILED
Dec 11, 2023 GNRT
NON-FINAL ACTION WRITTEN
Dec 11, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 13, 2023 DOCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 25, 2023 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 19, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 19, 2022 GNSL
SUSPENSION LETTER WRITTEN
Oct 19, 2022 CNSL
ASSIGNED TO EXAMINER
Sep 21, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 20, 2021 NWOS
NEW APPLICATION ENTERED
Dec 18, 2021 NWAP